DateTitle
27-11-2018 7:21 EST Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
13-11-2018 10:08 EST Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
9-11-2018 1:33 EST Nine-month interim report (Q3) 2018
5-11-2018 7:29 EST Release date of nine-month interim report (Q3) 2018 and audio cast
22-8-2018 14:17 UTC ALK submits registration application for tree SLIT-tablet in Europe
15-8-2018 5:37 UTC Six-month interim report (Q2) 2018
9-8-2018 10:21 CEST Release date of six-month interim report (Q2) 2018 and audio cast
4-5-2018 7:35 CEST Three-month interim report (Q1) 2018
1-5-2018 9:00 CEST Release date of three-month interim report (Q1) 2018 and audio cast
17-4-2018 12:40 CEST ALK’s partner for Japan, Torii, secures pricing for new Japanese cedar SLIT-tablet
11-4-2018 12:40 CEST ALK announces allergy diagnostic partnership with Rellergen in China
20-3-2018 16:19 CET Grant of share options and performance shares to members of the Board of Management and key employees
20-3-2018 15:44 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
16-3-2018 10:54 CET Articles of Association
12-3-2018 17:22 CET Annual General Meeting in ALK-Abelló A/S held on 12 March 2018
2-3-2018 16:49 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
21-2-2018 10:00 CET New medicine for house dust mite allergic rhinitis and allergic asthma now available in France
16-2-2018 7:00 CET ALK’s partner, Torii, gains paediatric approval for the house dust mite SLIT-tablet in Japan
13-2-2018 13:55 CET Annual General Meeting in ALK-Abelló A/S on 12 March 2018
6-2-2018 7:30 CET ALK releases its annual report 2017
30-1-2018 15:54 CET Release date of annual report 2017 and audio cast
11-1-2018 9:00 CET New Treatment for House Dust Mite (HDM) – Induced Allergic Rhinitis Now Available in US